Vol 9: Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlichs Ascites Carcinoma: Role of Angiotensin 1-7.Reportar como inadecuado



 Vol 9: Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlichs Ascites Carcinoma: Role of Angiotensin 1-7.


Vol 9: Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlichs Ascites Carcinoma: Role of Angiotensin 1-7. - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Descargar gratis o leer online en formato PDF el libro: Vol 9: Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlichs Ascites Carcinoma: Role of Angiotensin 1-7.
This article is from PLoS ONE, volume 9.AbstractLocal renin-angiotensin systems exist in various malignant tumor tissues; this suggests that the main effector peptide, angiotensin II, could act as a key factor in tumor growth. The underlying mechanisms for the anti-angiogenic effect of angiotensin II type 1 receptor blockers need to be further evaluated. The present study was carried out to investigate the anti-angiogenic effect of olmesartan alone or in combination with sorafenib, an angiotensin 1–7 agonist or an angiotensin 1–7 antagonist in Ehrlichs ascites carcinoma-bearing mice. The tumor was induced by intradermal injection of Ehrlichs ascites carcinoma cells into mice. Tumor discs were used to evaluate the microvessel density; the serum levels of vascular endothelial growth factor VEGF and serum insulin-like growth factor I IGF-I; and their intratumoral receptors, VEGF receptor-2 and IGF-I receptor, respectively. All parameters were determined following the treatment course, which lasted for 21 days post-inoculation. Monotherapy with olmesartan and its combination with sorafenib resulted in a significant reduction in microvessel density and serum levels of VEGF and IGF-I, as well as their intratumoral receptors. In addition, the combination of olmesartan 30 mg-kg with an angiotensin 1–7 agonist reduced the microvessel density, IGF-I serum levels and the levels of its intratumoral receptor. In conclusion, olmesartan reduced the levels of the angiogenesis markers IGF-I and VEGF and down-regulated the intratumoral expression of their receptors in a dose-dependent manner, and these effects were dependent on the angiotensin 1–7 receptor. These results suggest that olmesartan is a promising adjuvant to sorafenib in the treatment of cancer.



Autor: Abd-Alhaseeb, Mohammad M.; Zaitone, Sawsan A.; Abou-El-Ela, Soad H.; Moustafa, Yasser M.

Fuente: https://archive.org/







Documentos relacionados